Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15935768 | 0.92 | PDE4B (0.53) | PDE4BPDE4D | |
| SCHEMBL15921628 | 0.90 | PDE4B (0.47) | PDE4BPDE4DLMNAGAAALDH1A1 | |
| SCHEMBL15921020 | 0.87 | PDE4B (0.46) | PDE4BPDE4DLMNAALDH1A1TSHR | |
| SCHEMBL17290164 | 0.86 | PDE4B (0.47) | PDE4BPDE4DLMNAMEN1RAB9A | |
| SCHEMBL17290163 | 0.80 | LMNA (0.38) | PDE4BPDE4DLMNAALDH1A1TSHR | |
| SCHEMBL15921334 | 0.79 | PDE4B (0.53) | PDE4BPDE4DLMNAALDH1A1TSHR | |
| SCHEMBL17290216 | 0.79 | PDE4B (0.58) | PDE4BPDE4D | |
| SCHEMBL17290169 | 0.76 | LMNA (0.39) | PDE4BPDE4DLMNAALDH1A1TSHR | |
| SCHEMBL17290165 | 0.76 | PDE4B (0.42) | PDE4BPDE4DLMNAGAA | |
| SCHEMBL18868938 | 0.76 | PDE4B (0.49) | PDE4BPDE4DGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670189-B2 | Substituted condensed pyrimidine compounds | Grünenthal GmbH (DE) | 2017-06-06 | — | — | US | disclosed |
| EP-2951173-B1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2017-05-17 | — | — | EP | disclosed |
| US-20150344496-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344496-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | TYMP, PDE4A, DPYD | PDE4B 4/4885PDE4D 8/4885LMNA 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.